Company news

Outlook Therapeutics, Inc. (NASDAQ:OTLK) news

Outlook Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means…

Outlook Therapeutics, Inc. (NASDAQ:OTLK) news

Press releases & updates

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

Outlook Therapeutics Secures FDA Approval For LYTENAVA™

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics Announces New Employment Inducement Grants

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update